Early Access — free while we kick the tires
EdgarHawk

Legion Partners Asset Management, LLC

Director

Director 10% Owner

Latest: Director selling · June 2026

3 filings analyzed · 2 companies · Latest 2026-06-17

Never miss a filing from Legion Partners Asset Management, LLC

Watch this insider and we'll alert you the moment they file — at any company.

Companies

Company Buys Sells Direction
Clear Channel Outdoor Holdings, Inc. CCO 0 2 Net selling
LIFECORE BIOMEDICAL, INC. \DE\ LFCR 1 0 Net buying

Activity

June 2026
2026-06-17 Clear Channel Outdoor Holdings, Inc. CCO Joint filing
high
Sell
2,804,171 shares
$6,716,994
Significance 8/10

Director Raymond T. White sells 2.80M shares (96.9% of holdings) at $2.40 in 5 transactions totaling $6.7M at CCO

Director Raymond T. White executed 5 separate sales totaling 2,804,171 shares for $6,716,994.05 on 2026-06-15, reducing his holdings from 2,895,174 shares to 91,003 shares—a divestiture of 96.9% of his pre-transaction position. The sales occurred at $2.40 per share, which is -1.2% from the stock's 52-week high of $2.43 and near the top of the 52-week range. The company reported a latest-quarter net income of $-48,594,000.00, placing it in a loss position despite flat revenue of $373,864,000.00 and positive annual growth of 6.6%. This near-complete liquidation of a director's stake warrants scrutiny given the company's profitability challenges and the magnitude of shares being removed from insider ownership.

2026-06-11 Clear Channel Outdoor Holdings, Inc. CCO Joint filing
high
Sell
23,435,796 shares
$56,259,972
Significance 8/10

Director Raymond T. White sold 23,435,796 shares (99.1% of holdings) for $56.3M at Clear Channel Outdoor.

Director Raymond T. White executed three separate sales on 2026-06-09 totaling 23,435,796 shares for $56,259,971.87, reducing his holdings from 23,640,429 to 204,633 shares. This represents a near-complete exit of his position—selling 99.1% of his pre-transaction holdings at a blended average price of $2.40 per share. The company is currently unprofitable with net income of $-48,594,000.00 against quarterly revenue of $373,864,000.00, though annual revenue growth stands at +6.6%. The scale and completeness of this director-level divestiture during a period of operational losses warrants investor scrutiny of the company's financial trajectory and management's forward expectations.

October 2024
2024-10-07 LIFECORE BIOMEDICAL, INC. \DE\ LFCR Joint filing
high
Buy
1,463,414 shares
$5,999,997
Significance 7/10

Director Kiper buys 1,463,414 shares for $5,999,997.40 at $4.10; current price $5.09, down 40.5% from 52-week high.

Kiper Christopher S, a Director, executed 2 separate purchases totaling 1,463,414 shares for $5,999,997.40 at a blended average price of $4.10 per share. This acquisition is notable given the company's financial stress: LifeCore reported net income of -$16,230,000.00 in its latest quarter while generating $24,705,000.00 in revenue, and the stock is currently trading at $5.09, down 40.5% from its 52-week high of $8.55. The director's post-transaction holding of 319,286 shares contrasts with a pre-transaction position of -1,144,128 shares, indicating this purchase resolves a previous short or other negative position. The transaction represents a material capital commitment at a point of depressed valuation relative to recent historical range, though the company maintains positive annual revenue growth of 24.2% year-over-year.